Lifeward, Inc.
$3.4K 58 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Xiros Inc
Xiros Inc reported $3,393.24 across General Payments, Research, and Ownership to 4 physicians and teaching hospitals across 4 transactions.
- $3.4K Below-median payer
- All-tracks total
- 4 Below-median volume
- Transactions
- 4 Below-median reach
- Recipients
- −$13.9K
- General Payments vs PY2023
Xiros Inc reported $3,393.24 across all CMS Open Payments tracks (General + Research + Ownership) to 4 physicians and teaching hospitals in Program Year 2024 - ranking #1756 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,393.24, averaging $848.31 per recipient.
How Xiros Inc's $3.4K all-tracks total breaks down
Xiros Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer xiros-inc Xiros Inc
$3.4K · #1756/1,925 · 0.0% industry · PY2024
- TOT $3.4K
- RANK #1756
- SHARE 0.0%
- TXN 4
- RCP 4
- CAT 2
- GEN $3.4K
- ΔGEN −$13.9K
- TOP1 92.8%
- PY 2024
Volume peers
Nearest volume peer: Lifeward, Inc. ($3.4K)
Xiros Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Xiros Inc's CMS-reported General Payments decreased by $13.9K (−80.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: XIROS INCPY2023: XIROS INCPY2024: Xiros Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $17,282.36
- PY2024
- $3,393.24
What the Data Shows for Xiros Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Xiros Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $3.1K across 2 transactions, 92.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Xiros Inc's largest category was "Consulting Fee" at $3.1K - 92.8% of General Payments.
How Xiros Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $3.1K | 2 | 92.8% |
| Food and Beverage | $243.24 | 2 | 7.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,393.24 (100.0%) of $3,393.24 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Xiros Inc
The five named recipients with the highest reported General Payments from this company
- 1
Kyle Borque
$3,150.00 across 2 reported transactions
- 2
Kenneth R Brooks
$146.57 across 1 reported transactions
- 3
David S Jevsevar
$96.67 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Xiros Inc ranks #1756 of 1,925 by total payments (bottom 9% by spend) but is notably more concentrated than that alone would suggest -- #185 of 1,838 by HHI (top 10% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Jubilant HollisterStier LLC : $81.7K total payments, HHI 8863
- Nonin Medical, Inc. : $7.0K total payments, HHI 8748
- American Surgical Company, LLC : $18.8K total payments, HHI 8733
- Jubilant DraxImage Inc. : $17.7K total payments, HHI 8710
- Elucid Bioimaging Inc : $130.1K total payments, HHI 8681
- Biolase MG LLC : $11.5K total payments, HHI 8681
- Xiros Inc (this company) : $3.4K total payments, HHI 8644
- Emmaus Medical, Inc. : $197.9K total payments, HHI 8631
- OrthoPediatrics Canada ULC : $104.0K total payments, HHI 8624
- Sequoia Surgical Distributors, LLC : $65.8K total payments, HHI 8574
- Auxano Medical LLC : $8.8K total payments, HHI 8543
- Swan Valley Medical Incorporated : $65.3K total payments, HHI 8507
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Xiros Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Xiros Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Xiros Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Meitheal Pharmaceuticals, Inc.
$3.3K 9 recipients
Compare payment profiles
BonaliveInc
$3.3K 34 recipients
Compare payment profiles
Northern X-Ray Company
$3.3K 2 recipients
Compare payment profiles
Pillar Biosciences, Inc
$3.3K 8 recipients
Compare payment profiles
Avion Pharmaceuticals
$3.5K 159 recipients
Compare payment profiles
Put this to use
Xiros Inc ranks #1756 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Xiros Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.